Queensland Children's Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04496245
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Queensland Children's Hospital | Queensland Children's Hospital, Brisbane, Australia

Active Ingredients

Drugs in Phase 3 Trials (1)

Bacterial Lysates (pulmonarom) (1 trial)

Drugs in Phase 2 Trials (1)

triheptanoin (Dojolvi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Ataxia Telangiectasia (Phase 2)

Cerebellar Ataxia (Phase 2)

Telangiectasis (Phase 2)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2